A183490 Stock Overview
Engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Enzychem Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,281.00 |
| 52 Week High | ₩2,220.00 |
| 52 Week Low | ₩1,230.00 |
| Beta | 1.51 |
| 11 Month Change | -12.08% |
| 3 Month Change | -19.94% |
| 1 Year Change | -16.93% |
| 33 Year Change | -86.70% |
| 5 Year Change | -86.61% |
| Change since IPO | -75.87% |
Recent News & Updates
Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 13
There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price
Aug 13Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt
May 09Recent updates
Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 13There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price
Aug 13Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt
May 09If You Had Bought Enzychem Lifesciences (KOSDAQ:183490) Shares A Year Ago You'd Have Earned 43% Returns
Feb 17
Shareholder Returns
| A183490 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.5% | -0.9% | 0.9% |
| 1Y | -16.9% | 7.7% | -3.4% |
Return vs Industry: A183490 underperformed the KR Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: A183490 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
| A183490 volatility | |
|---|---|
| A183490 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A183490 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A183490's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 123 | Ki-Young Sohn | www.enzychem.com |
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
Enzychem Lifesciences Corporation Fundamentals Summary
| A183490 fundamental statistics | |
|---|---|
| Market cap | ₩102.83b |
| Earnings (TTM) | -₩7.86b |
| Revenue (TTM) | ₩82.07b |
1.2x
P/S Ratio-13.0x
P/E RatioIs A183490 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A183490 income statement (TTM) | |
|---|---|
| Revenue | ₩82.07b |
| Cost of Revenue | ₩76.91b |
| Gross Profit | ₩5.17b |
| Other Expenses | ₩13.02b |
| Earnings | -₩7.86b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -98.42 |
| Gross Margin | 6.30% |
| Net Profit Margin | -9.57% |
| Debt/Equity Ratio | 2.0% |
How did A183490 perform over the long term?
See historical performance and comparison